Nanologica AB (NICA) - Total Liabilities
Based on the latest financial reports, Nanologica AB (NICA) has total liabilities worth Skr164.82 Million SEK (≈ $17.74 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Nanologica AB (NICA) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Nanologica AB - Total Liabilities Trend (2012–2025)
This chart illustrates how Nanologica AB's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Nanologica AB balance sheet assets.
Nanologica AB Competitors by Total Liabilities
The table below lists competitors of Nanologica AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Libet S.A.
WAR:LBT
|
Poland | zł22.31 Million |
|
Blende Silver Corp
V:BAG
|
Canada | CA$455.80K |
|
ClearOne Inc
NASDAQ:CLRO
|
USA | $1.49 Million |
|
Refinaria de Petróleos de Manguinhos S.A
SA:RPMG3
|
Brazil | R$17.72 Billion |
|
Melewar Industrial Group Bhd
KLSE:3778
|
Malaysia | RM181.72 Million |
|
Origin Agritech Ltd
NASDAQ:SEED
|
USA | $168.09 Million |
|
Lion Metal Works Tbk
JK:LION
|
Indonesia | Rp153.18 Billion |
|
Scandinavian Medical Solutions AS
CO:SMSMED
|
Denmark | Dkr123.19 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Nanologica AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See NICA equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.69 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.63 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nanologica AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nanologica AB (2012–2025)
The table below shows the annual total liabilities of Nanologica AB from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr65.47 Million ≈ $7.05 Million |
-5.10% |
| 2024-12-31 | Skr68.99 Million ≈ $7.42 Million |
-13.03% |
| 2023-12-31 | Skr79.33 Million ≈ $8.54 Million |
-2.49% |
| 2022-12-31 | Skr81.36 Million ≈ $8.76 Million |
+74.13% |
| 2021-12-31 | Skr46.72 Million ≈ $5.03 Million |
-12.48% |
| 2020-12-31 | Skr53.38 Million ≈ $5.74 Million |
+39.87% |
| 2019-12-31 | Skr38.16 Million ≈ $4.11 Million |
+259.34% |
| 2018-12-31 | Skr10.62 Million ≈ $1.14 Million |
-55.70% |
| 2017-12-31 | Skr23.98 Million ≈ $2.58 Million |
+143.71% |
| 2016-12-31 | Skr9.84 Million ≈ $1.06 Million |
+14.02% |
| 2015-12-31 | Skr8.63 Million ≈ $928.58K |
-24.54% |
| 2014-12-31 | Skr11.43 Million ≈ $1.23 Million |
+252.85% |
| 2013-12-31 | Skr3.24 Million ≈ $348.74K |
+20.11% |
| 2012-12-31 | Skr2.70 Million ≈ $290.36K |
-- |
About Nanologica AB
Nanologica AB (publ), a life science tools company, develops, manufactures, and sells nanoporous silica particles in China, India, Turkey, the United States, and internationally. The company offers NLAB Saga, a silica-based purification media for preparative chromatography that is developed for the purification of peptide drugs, such as insulin and GLP-1 analogues; NLAB Idun, an ion exchange prod… Read more